Clinical trials: Paclitaxel, completed
Recurrent Ovarian Carcinoma
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with…
- Trial name
- NCT03353831
- Testing
- Bevacizumab, Atezolizumab, Chemotherapy
- Where
- 111 sites in Austria, Belgium and 10 more
- Volunteers
- 574 people
- Sponsor
- AGO Research GmbH
Advanced Malignant Solid Tumors
Study Evaluating Safety And Tolerability, Solid Tumor
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
- Trial name
- NCT00768469
- Testing
- Neratinib, Paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Puma Biotechnology, Inc.
Cancer, Non-Small Cell Lung Cancer
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase.
- Conditions
- Cancer, Non-Small Cell Lung Cancer, Endometrial Carcinoma, Ovarian Carcinoma
- Trial name
- NCT00756847
- Testing
- XL147 (SAR245408),, paclitaxel, carboplatin
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer (NSCLC)
The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients
The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients
- Trial name
- OPTIMUS (NCT04909164)
- Testing
- Immunnotherapy group
- Where
- South Korea
- Volunteers
- 1,519 people
- Sponsor
- Myung-Ju Ahn
Atherosclerosis, Angioplasty
Local Paclitaxel Delivery for SFA Disease
To see if restenosis rates of superficial femoral artery atherosclerosis with percutaneous techniques can be improved using paclitaxel.
- Conditions
- Atherosclerosis, Angioplasty, Peripheral Arterial Disease
- Trial name
- IRRITAX (NCT00821028)
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Oklahoma
Nonsquamous Nonsmall Cell Neoplasm of Lung
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
- Trial name
- ANGIOMET (NCT01814163)
- Testing
- paclitaxel, carboplatin and bevacizumab
- Where
- 20 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Lung Cancer Group
Peripheral Arterial Disease, Cardiovascular Disease
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and…
- Conditions
- Peripheral Arterial Disease, Cardiovascular Disease, Peripheral Vascular Disease
- Trial name
- COPPER-A (NCT02464501)
- Testing
- Paclitaxel administration using the OPC
- Where
- 17 sites in United States
- Volunteers
- 112 people
- Sponsor
- Horizons International Peripheral Group
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003111
- Testing
- carboplatin, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Breast Cancer
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared…
- Trial name
- ETNA (NCT01822314)
- Testing
- Abraxane, Paclitaxel
- Where
- 67 sites in Australia, Germany and 4 more
- Volunteers
- 632 people
- Sponsor
- Fondazione Michelangelo
Urothelial Carcinoma
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer. Each cycle last 21-days.
- Trial name
- ABLE (NCT03240016)
- Testing
- Pembrolizumab, Abraxane
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006004
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 16 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003133
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of TLR8 agonist VTX-2337 and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or…
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT01294293
- Testing
- TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
The purpose of this study is to determine whether a treatment with 4 cycles anthracycline + cyclophoshamide followed by administration of 4 cycles paclitaxel is more effective than therapy with 4 cy<cles of anthracycline…
- Trial name
- NCT00668616
- Testing
- Cyclophosphamide, Epirubicin, Paclitaxel, Epirubicin, Paclitaxel, Filgrastim
- Where
- Germany
- Volunteers
- 1,034 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Non-Hodgkin's Lymphoma
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
- Trial name
- NCT00038545
- Testing
- Filgrastim SD/01, Paclitaxel, Topotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.
- Trial name
- NCT00483301
- Testing
- Sorafenib (BAY 43-9006), ABI-007(Abraxane)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mt. Sinai Medical Center, Miami
HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive…
- Conditions
- HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02654119
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery.
- Conditions
- Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02930902
- Testing
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004126
- Testing
- oxaliplatin, paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.